Enasidenib mesylate - Generic Drug Details

✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions

What are the generic sources for enasidenib mesylate and what is the scope of patent protection?

Enasidenib mesylate is the generic ingredient in one branded drug marketed by Celgene Corp and is included in one NDA. There are six patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Enasidenib mesylate has one hundred and eight patent family members in thirty-nine countries.

One supplier is listed for this compound.

Summary for enasidenib mesylate

International Patents:	108
US Patents:	6
Tradenames:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	19
Clinical Trials:	6
Patent Applications:	255
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for enasidenib mesylate
What excipients (inactive ingredients) are in enasidenib mesylate?	enasidenib mesylate excipients list
DailyMed Link:	enasidenib mesylate at DailyMed

Recent Clinical Trials for enasidenib mesylate

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Children's Oncology Group	Phase 2
City of Hope Medical Center	Phase 1
National Cancer Institute (NCI)	Phase 1

See all enasidenib mesylate clinical trials

Pharmacology for enasidenib mesylate

Drug Class	Isocitrate Dehydrogenase 2 Inhibitor
Mechanism of Action	Isocitrate Dehydrogenase 2 Inhibitors

US Patents and Regulatory Information for enasidenib mesylate

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Try it Free
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Celgene Corp	IDHIFA	enasidenib mesylate	TABLET;ORAL	209606-001	Aug 1, 2017		RX	Yes	No	See Plans and Pricing	See Plans and Pricing		Y		See Plans and Pricing
Celgene Corp	IDHIFA	enasidenib mesylate	TABLET;ORAL	209606-002	Aug 1, 2017		RX	Yes	Yes	See Plans and Pricing	See Plans and Pricing				See Plans and Pricing
Celgene Corp	IDHIFA	enasidenib mesylate	TABLET;ORAL	209606-002	Aug 1, 2017		RX	Yes	Yes	See Plans and Pricing	See Plans and Pricing		Y		See Plans and Pricing
Celgene Corp	IDHIFA	enasidenib mesylate	TABLET;ORAL	209606-001	Aug 1, 2017		RX	Yes	No	See Plans and Pricing	See Plans and Pricing	Y	Y		See Plans and Pricing
Celgene Corp	IDHIFA	enasidenib mesylate	TABLET;ORAL	209606-001	Aug 1, 2017		RX	Yes	No	See Plans and Pricing	See Plans and Pricing				See Plans and Pricing
Celgene Corp	IDHIFA	enasidenib mesylate	TABLET;ORAL	209606-002	Aug 1, 2017		RX	Yes	Yes	See Plans and Pricing	See Plans and Pricing		Y		See Plans and Pricing
Celgene Corp	IDHIFA	enasidenib mesylate	TABLET;ORAL	209606-002	Aug 1, 2017		RX	Yes	Yes	See Plans and Pricing	See Plans and Pricing	Y	Y		See Plans and Pricing
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

International Patents for enasidenib mesylate

Subscribe to access the full database, or Try it Free
Country	Patent Number	Title	Estimated Expiration
China	104114543	Therapeutically active compounds and their methods of use	See Plans and Pricing
Japan	6742905		See Plans and Pricing
European Patent Office	3984997	COMPOSÉS THÉRAPEUTIQUEMENT ACTIFS ET LEURS PROCÉDÉS D'UTILISATION (THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE)	See Plans and Pricing
South Africa	201405163	THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE	See Plans and Pricing
Japan	2015503571	治療活性化合物およびその使用方法	See Plans and Pricing
Mexico	2016001361	COMPUESTOS TERAPEUTICAMENTE ACTIVOS Y SUS METODOS DE USO. (THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE.)	See Plans and Pricing
Poland	2800743		See Plans and Pricing
>Country	>Patent Number	>Title	>Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.